Vaxcyte (PCVX) Cash & Equivalents (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Cash & Equivalents data on file, last reported at $260.8 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 24.8% year-over-year to $260.8 million in Q1 2026; TTM through Mar 2026 was $260.8 million, a 24.8% decrease from a year earlier, with the FY2025 full-year figure at $174.0 million, down 55.15% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $260.8 million, up from $174.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for PCVX reached as high as $1.1 billion in Q3 2024 and fell as low as $174.0 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $432.0 million across 5 years, with a median of $380.5 million in 2023.
• Across the five-year window, Cash & Equivalents soared 1109.91% in 2022 and tumbled 73.24% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $834.7 million in 2022, then plunged by 52.38% to $397.5 million in 2023, then fell by 2.41% to $387.9 million in 2024, then slumped by 55.15% to $174.0 million in 2025, then soared by 49.95% to $260.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $260.8 million in Q1 2026, $174.0 million in Q4 2025, and $281.1 million in Q3 2025.